Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02146222 · ClinicalTrials.gov registry record · Phase 1
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02146222 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants.
The verdict
NCT02146222, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This partially randomized phase I trial studies the side effects and how well sequential dosing of vascular endothelial growth factor receptor (VEGFR)/platelet derived growth factor receptor (PDGFR) dual kinase inhibitor X-82 and docetaxel works in treating patients with solid tumors. VEGFR/PDGFR dual kinase inhibitor X-82 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving VEGFR/PDGFR dual kinase inhibitor X-82 and docetaxel one at a time instead of concurrently may work in treating patients with solid tumors.
Interventions
- DRUG docetaxel
- OTHER pharmacological study
- OTHER fluorine F 18 fluorothymidine
- PROCEDURE positron emission tomography/computed tomography
- DRUG VEGFR/PDGFR dual kinase inhibitor X-82
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02146222
The ClinicalTrials.gov registry entry for NCT02146222 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which docetaxel is the first listed.
NCT02146222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02146222 about?
NCT02146222 is a clinical study titled "VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors". This partially randomized phase I trial studies the side effects and how well sequential dosing of vascular endothelial growth factor receptor (VEGFR)/platelet derived growth factor receptor (PDGFR) dual kinase inhibitor X-82 and docetaxel works in treating patients with solid tumors. VEGFR/PDGFR du...
What is the current status of trial NCT02146222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2014-09. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02146222?
The interventions under investigation include: docetaxel (DRUG), pharmacological study (OTHER), fluorine F 18 fluorothymidine (OTHER), positron emission tomography/computed tomography (PROCEDURE), VEGFR/PDGFR dual kinase inhibitor X-82 (DRUG).
Who is sponsoring clinical trial NCT02146222?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.